Budesonide Cir Capsules (Once Or Twice Daily Divided-Dose) in Active Crohn's Disease: A Randomized Placebo-Controlled Study in The United States

Abstract

Treatment of symptomatic Crohn's disease with budesonide CIR capsules (9 mg daily) was safe, and remission rates were similar to those achieved in previous trials. Although the remission rate did not significantly differ from the placebo response in this study, there was a significant change in the mean CDAI from baseline in the combined treatment groups relative to the placebo.